Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Essendon, Australia Clinical Trials

A listing of Essendon, Australia clinical trials actively recruiting patients volunteers.

Found (219) clinical trials

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.

Phase

4.2 miles

Learn More »

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.

Phase

4.2 miles

Learn More »

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Eligible subjects (i.e., those meeting the Inclusion / Exclusion criteria) will be enrolled in one of four cohorts based on the following criteria: Cohort 1: All eligible subjects in the PoI who are 18 year old subjects with a PIV infection and meet all of the following criteria: 1.1 Meet …

Phase

4.2 miles

Learn More »

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Patients will be randomized 1:1 to either bardoxolone methyl or placebo. Patients receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate …

Phase

4.2 miles

Learn More »

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

Phase

4.2 miles

Learn More »

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

Acute intracerebral haemorrhage (ICH) is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur globally each year. Survivors of ICH are at high risk of recurrent ICH and other serious cardiovascular events. While there is strong evidence …

Phase

4.2 miles

Learn More »

Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab

This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of EBV+ PTLD in the setting of allogeneic HCT after failure of rituximab. Tabelecleucel will be selected for the subject from the bank of available tabelecleucel cell products based …

Phase

4.2 miles

Learn More »

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

Cognitive decline and dementia in ICH is high due to the common underlying vasculopathy of cerebral small vessel disease (CSVD). However, in general, detailed cognitive outcomes in ICH have been neglected, possibly due to the high mortality rate of ICH (up to 60% within the first year). Blood pressure (BP) …

Phase

4.2 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

This study is designed 1) to describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in pneumococcal vaccine-nave adult and pediatric recipients of allogeneic hematopoietic stem cell transplant (HSCT), and 2) to describe the safety and tolerability of PNEUMOVAX23 when administered 12 months after HSCT.

Phase

4.2 miles

Learn More »

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

The primary objective of this prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group, Phase 3 study is to determine the effect of oral lucerastat monotherapy on neuropathic pain in subjects with Fabry disease (FD) through daily collection of patient-reported outcomes with an electronic diary.

Phase

4.2 miles

Learn More »